Artiva Biotherapeutics (NASDAQ:ARTV) Given Outperform Rating at Wedbush

Wedbush restated their outperform rating on shares of Artiva Biotherapeutics (NASDAQ:ARTV) in a report released on Tuesday,Benzinga reports. The brokerage currently has a $18.00 price target on the stock. Wedbush also issued estimates for Artiva Biotherapeutics’ Q1 2025 earnings at ($0.62) EPS, Q2 2025 earnings at ($0.66) EPS, Q3 2025 earnings at ($0.70) EPS, Q4 2025 earnings at ($0.57) EPS, FY2025 earnings at ($2.54) EPS, FY2026 earnings at ($2.68) EPS, FY2027 earnings at ($2.82) EPS and FY2028 earnings at ($2.95) EPS.

Several other research analysts have also commented on the company. Needham & Company LLC reissued a “buy” rating and issued a $23.00 price target on shares of Artiva Biotherapeutics in a research report on Tuesday. HC Wainwright initiated coverage on shares of Artiva Biotherapeutics in a report on Monday, December 30th. They issued a “buy” rating and a $20.00 price target for the company. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, Artiva Biotherapeutics presently has a consensus rating of “Buy” and an average target price of $20.40.

Artiva Biotherapeutics Stock Performance

NASDAQ:ARTV opened at $3.54 on Tuesday. The firm has a 50-day simple moving average of $4.78 and a 200-day simple moving average of $9.29. Artiva Biotherapeutics has a one year low of $3.37 and a one year high of $17.31.

Hedge Funds Weigh In On Artiva Biotherapeutics

Several institutional investors and hedge funds have recently modified their holdings of ARTV. State Street Corp acquired a new position in shares of Artiva Biotherapeutics in the third quarter worth about $1,337,000. Geode Capital Management LLC acquired a new stake in shares of Artiva Biotherapeutics in the third quarter valued at about $4,774,000. Barclays PLC purchased a new position in Artiva Biotherapeutics in the 3rd quarter worth approximately $304,000. BNP Paribas Financial Markets purchased a new position in Artiva Biotherapeutics during the third quarter worth approximately $42,000. Finally, JPMorgan Chase & Co. purchased a new position in shares of Artiva Biotherapeutics during the 3rd quarter worth $166,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.